ABCC7 p.Phe1337Val

ClinVar: c.4009T>G , p.Phe1337Val ? , not provided
CF databases: c.4009T>G , p.Phe1337Val (CFTR1) D , The mutation was detected by DGGE and identified by direct sequencing in a CBAVD patient with R1070Q on the other allele. The mutation creates a MaeII site. It was not detected in 50 unrelated individuals with no CF history.
Predicted by SNAP2: A: N (78%), C: N (78%), D: D (63%), E: N (57%), G: N (57%), H: N (66%), I: N (72%), K: N (53%), L: N (66%), M: N (72%), N: N (61%), P: D (63%), Q: N (78%), R: D (71%), S: N (93%), T: N (93%), V: N (72%), W: D (71%), Y: N (93%),
Predicted by PROVEAN: A: N, C: N, D: D, E: N, G: D, H: N, I: N, K: D, L: N, M: N, N: N, P: D, Q: N, R: N, S: N, T: N, V: N, W: N, Y: N,

[switch to compact view]
Comments [show]
Publications
[hide] Krasnov KV, Tzetis M, Cheng J, Guggino WB, Cutting GR
Localization studies of rare missense mutations in cystic fibrosis transmembrane conductance regulator (CFTR) facilitate interpretation of genotype-phenotype relationships.
Hum Mutat. 2008 Nov;29(11):1364-72., [PMID:18951463]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Dorfman R, Nalpathamkalam T, Taylor C, Gonska T, Keenan K, Yuan XW, Corey M, Tsui LC, Zielenski J, Durie P
Do common in silico tools predict the clinical consequences of amino-acid substitutions in the CFTR gene?
Clin Genet. 2010 May;77(5):464-73. Epub 2009 Jan 6., [PMID:20059485]

Abstract [show]
Comments [show]
Sentences [show]